Nasal Vaccine Articles & Analysis
5 news found
Clínica Universidad de Navarra has completed a randomised controlled study of Ondine Biomedical’s nasal photodisinfection technology in fully vaccinated COVID-19 patients with early symptoms of COVID-19. “Top-line results from this clinical trial suggest that nasal photodisinfection treatment rapidly and substantially ...
Since the discovery of RSV in 1956, no vaccine has been approved for prevention. “We believe that our intranasal live attenuated RSV vaccine candidate, developed on Meissa’s AttenuBlockTM vaccine platform, offers the potential to finally immunize against RSV, which has evaded other vaccine technologies for ...
Meissa is developing MV-012-968, an intranasal (needle-free), live attenuated vaccine candidate, to protect infants and at-risk, older adults from RSV. ...
Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines through its patented NanoVax™ adjuvant, today announced a ...
Furthermore, building our COVID-19 vaccine candidate on our RSV vaccine platform provides safety advantages compared to a live attenuated coronavirus ...